About Gliclazide
            
            Class: | Sulfonylurea (antidiabetic agent)  
Use: | Management of type 2 diabetes mellitus, particularly in patients who are not adequately controlled on diet and exercise alone  
Adult dose: | Initial dose is typically 30 mg once daily, which may be increased to a maximum of 120 mg per day based on blood glucose levels; for G-ZIDE MR, the standard dose is 60 mg once daily  
Pediatric dose: | Not established; safety and efficacy in pediatric patients have not been determined  
Side effects: | Co
         
        
            
                
                
                    
                        Drug Class
                    
                    Sulfonylurea (antidiabetic agent)
                 
                
                
                    
                        Uses & Indications
                    
                    Management of type 2 diabetes mellitus, particularly in patients who are not adequately controlled on diet and exercise alone
                 
                
                
                    
                        Storage Requirements
                    
                    Store below 30°C (86°F) in a dry place, protected from light
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: OMAN PHARMACEUTICAL PRODUCTS CO.  L.L.C (ZYNOVA)[Salalah;Oman], Oman
                    
                    
                    Package Size
                    28'S(14's Blister x 2)
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 20.50
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose is typically 30 mg once daily, which may be increased to a maximum of 120 mg per day based on blood glucose levels; for G-ZIDE MR, the standard dose is 60 mg once daily
                    
                    
                        Pediatric Dose
                    
                    
                        Not established; safety and efficacy in pediatric patients have not been determined
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include hypoglycemia, weight gain, gastrointestinal disturbances (nausea, vomiting), dizziness, and headache
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to gliclazide or any component of the formulation, type 1 diabetes mellitus, diabetic ketoacidosis, severe renal or hepatic impairment
         
        
        
            
                Important Warnings
            
            Risk of hypoglycemia, especially in elderly patients or those with renal impairment; monitor blood glucose levels regularly; caution in patients with cardiovascular disease or those taking other medications that may affect blood sugar levels
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.